[1]胥 然,张礼俊,季语祝,等.原发性喉癌组织中miR-425-5p/PTCH1轴分子表达与临床病理特征及预后关系研究[J].现代检验医学杂志,2025,40(04):50-54,66.[doi:10.3969/j.issn.1671-7414.2025.04.009]
　XU Ran,ZHANG Lijun,JI Yuzhu,et al.Study on the Relationship between miR-425-5p/PTCH1 Axis Molecular Expression and Clinical Pathological Characteristics and Prognosis in Primary Laryngeal Cancer Tissue[J].Journal of Modern Laboratory Medicine,2025,40(04):50-54,66.[doi:10.3969/j.issn.1671-7414.2025.04.009]
点击复制

原发性喉癌组织中miR-425-5p/PTCH1轴分子表达与临床病理特征及预后关系研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年04期
页码:
50-54,66
栏目:
论著
出版日期:
2025-07-15

文章信息/Info

Title:
Study on the Relationship between miR-425-5p/PTCH1 Axis Molecular Expression and Clinical Pathological Characteristics and Prognosis in Primary Laryngeal Cancer Tissue
文章编号:
1671-7414（2025）04-050-06
作者:
胥 然a，张礼俊a，季语祝b，张 爽a，蒋振华a
（绵阳市中心医院 a. 耳鼻喉科；b. 病理科，四川绵阳 621000）
Author(s):
XU Rana，ZHANG Lijuna，JI Yuzhub，ZHANG Shuanga，JIANG Zhenhuaa
(a. Department of Otolaryngology； b. Department of Pathology，Mianyang Central Hospital, Sichuan Mianyang 621000，China)
关键词:
原发性喉癌; 癌组织; 微小RNA-425-5p/Patched homolog1 轴; 临床病理参数
分类号:
R739.5；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.04.009
文献标志码:
A
摘要:
目的 研究原发性喉癌（PLC）患者癌组织中微小RNA（miR）-425-5p/ Patched homolog1(PTCH1) 轴分子与临床病理参数及预后的关系。方法 选择绵阳市中心医院2020 年3 月～ 2021 年3 月收治的102 例PLC 患者，比较PLC癌组织及癌旁正常组织中miR-425-5p 相对表达量、PTCH1 阳性表达率，分析miR-425-5p 相对表达量、PTCH1 阳性表达率与PLC 临床病理参数间的关系；采用Kaplan-Meier 曲线和Log-Rank χ2 检验分析miR-425-5p，PTCH1 阳性/ 阴性表达组三年累积生存率；采用COX 回归模型分析PLC 预后的影响因素。结果 相较于癌旁正常组织，PLC 癌组织miR-425-5p 相对表达量明显升高（2.12±0.52 vs 0.98±0.17），PTCH1 阳性表达率明显降低（27.45% vs 61.76%），差异具有统计学意义（t/χ2=21.045，24.302，均P ＜ 0.05）。相较于肿瘤T1 ～ T2 期、N0 期、中高分化患者，肿瘤T3 ～ T4 期、N1~N3 期、低分化患者miR-425-5p 相对表达量明显升高（t=3.647，2.900，3.029），PTCH1 阳性表达率明显降低（χ2=5.842，4.011，5.136），差异具有统计学意义（均P ＜ 0.05）。miR-425-5p 高表达组三年累积生存率[64.52%（20/31）] 明显低于低表达组[84.06%（58/69）]，PTCH1 高表达组三年累积生存率[80.00%（28/35）] 明显高于低表达组[64.62%（42/65）]，差异具有统计学意义（Log-Rank χ2=4.287，4.548，均P<0.05）。T 分期升高、颈淋巴结复发、N 分期升高、咽喉部复发、miR-425-5p 升高、PTCH1 阴性表达是PLC 预后不良的危险因素（均P ＜ 0.05）。结论 PLC 患者癌组织中miR-425-5p高表达、PTCH1 低表达与T 分期升高、肿瘤低分化、N 分期升高和三年累积生存率低显著相关。
Abstract:
Objective To investigate the relationship between microRNA (miR) -425-5p/patched homolog 1(PTCH1) axis molecules and clinical pathological parameters and prognosis in cancer tissues of primary laryngeal cancer (PLC) patients. Methods 102 PLC patients admitted to Mianyang Central Hospital from March 2020 to March 2021 were selected. The relative expression level of miR-425-5p and PTCH1 positive expression rate in PLC cancer tissues and adjacent normal tissues were compared, and the relationship between miR-425-5p relative expression level, PTCH1 positive expression rate and PLC clinical pathological parameters was analyzed. Kaplan-Meier curve and Log-Rank were used χ2 tests were conducted to analyze the 3-year cumulative survival rate of miR-425-5p and PTCH1 positive/negative expression groups，and COX regression model was used to analyze the influencing factors of PLC prognosis. Results Compared with normal tissue adjacent to cancer, the relative expression level of miR-425-5p in PLC cancer tissue was significantly increased（2.12±0.52 vs 0.98±0.17）, and the positive expression rate of PTCH1 was significantly reduced(27.45% vs 61.76%）, with statistical significance(t/χ2=21.045，24.302，all P ＜ 0.05）. Compared with patients with T1-T2, N0, and high differentiation of tumors, patients with T3-T4, N1-N3, and low differentiation of tumors showed a significant increase in the relative expression of miR-425-5p (t=3.647, 2.900, 3.029), and a significant decrease in the positive expression rate of PTCH1 (χ2=5.842, 4.011, 5.136), the differences were statistically significance (all P<0.05). The 3-year cumulative survival rate of the miR-425-5p high expression group was 64.52% (20/31), which was significantly lower than that of the low expression group at 84.06% (58/69). The 3-year cumulative survival rate of the PTCH1 high expression group was 80.00% (28/35), which was significantly higher than that of the low expression group at 64.62% (42/65), and the differences were statistically significant (Log-Rank χ2=4.287, 4.548, all P<0.05). Elevated T taging, cervical lymph node recurrence, elevated N staging, pharyngeal recurrence, elevated miR-425-5p, and negative PTCH1 expression were risk factors for poor prognosis of PLC (all P<0.05). Conclusion High expression of miR-425-5p and low expression of PTCH1 in cancer tissues of primary laryngeal cancer patients are significantly correlated with elevated T stage, low tumor differentiation, elevated N stage, and low 3-year cumulative survival rate.

参考文献/References:

[1] 王川, 刘盼, 神平, 等. 外周血中性粒细胞与淋巴细胞比值以及血小板与淋巴细胞比值评估声门型喉癌患者预后的价值[J]. 中国耳鼻咽喉颅底外科杂志,2021,27(3):300-304. WANG C, LIU P, SHEN P, et al. Prognostic values of peripheral blood neutrophil-to-lymphocyte ratio and plateletto-lymphocyte ratio in patients with glottic laryngeal squamous cell carcinomas[J]. Chinese Journal of Otorhinolaryngologyskull Base Surgery, 2021, 27(3): 300-304.
[2] 杨荣松, 杨琛, 魏璐璐. 血清PTTG1 TK1 LncRNA水平在原发性喉癌临床诊断及疗效预测中的价值[J]. 安徽医学,2023,44(3):284-288. YANG R S, YANG C, WEI L L. Value of levels of serum PTTG1 TK1 and LncRNA in clinical diagnosis and efficacy prediction of primary laryngeal cancer[J]. Anhui Medical Journal, 2023, 44(3): 284-288.
[3] 屈慧, 皇海, 张蕊. 血清细胞角蛋白18、骨桥蛋白水平与原发性喉癌患者临床分期相关性研究[J]. 陕西医学杂志,2021,50(11):1452-1456. QU H, HUANG H, ZHANG R. Correlation between serum cytokeratin 18 ,osteopontin levels and clinical stage of patients with primary laryngeal carcinoma[J]. Shaanxi Medical Journal, 2021, 50(11): 1452-1456.
[4] 国家癌症中心, 国家肿瘤质控中心喉癌质控专家委员会. 中国原发性喉癌规范诊疗质量控制指标(2022版)[J]. 中华肿瘤杂志,2022,44(12):1235-1241. National Cancer Cente，Laryngeal Cancer Expert Committee of National Cancer Quality Control Center. Quality control index for standardized diagnosis and treatment of laryngeal cancer in China (2022 edition) [J]. Chinese Journal of Oncology, 2022, 44(12): 1235-1241.
[5] 赵珍珍, 常淼, 皇甫辉.MicroRNA 在喉癌调控机制中的研究进展[J]. 中国全科医学,2021,24(S2):8-14. ZHAO Z Z, CHANG M, HUANGFU H. Research progress of microRNA in regulation of laryngeal cancer[J]. Chinese General Practice, 2021, 24(S2): 8-14.
[6] 张杨蕊, 庞霞, 黄培, 等.miR-425-5p 通过调控PTEN促进乳腺癌细胞体外生长和转移的机制[J]. 实用癌症杂志,2020,35(12):1943-1949. ZHANG Y R, PANG X, HUANG P et al. MiR-425-5p promotes growth and metastasis of breast cancer cells in vitro by regulating PTEN[J]. the Practical Journal of Cancer, 2020, 35(12): 1943-1949.
[7] 何贞月, 王莹. 晚期结直肠癌患者血清miR-143-3p,miR-425-5p 表达水平及其与化疗敏感性、预后的关系[J]. 临床医学研究与实践,2021,6(23):7-10． HE Z Y, WANG Y. Expression levels of serum miR-143-3p and miR-425-5p in patients with advanced colorectal cancer and their relationship with chemosensitivity and prognosis [J]. Clinical Research and Practice, 2021, 6(23): 7-10.
[8] 朱凌霄, 沈冰, 刘陶文, 等. 鼻咽癌中Ptch1 和Ptch2基因的表达及关系[J]. 广东医学,2017,38(20):3102-3107. ZHU L X, SHEN B, LIU T W, et al. The correlation between Ptch1 and Ptch2 expression in nasopharyngeal carcinoma[J]. Guangdong Medical Journal, 2017, 38(20): 3102-3107.
[9] 郑芳, 徐浩.PTCH1 基因通过Hedgehog 信号通路对卵巢癌细胞增殖和凋亡影响[J]. 中国计划生育学杂志,2021,29(12):2503-2507. ZHENG F, XU H. Effect of PTCH1 gene on the proliferation and apoptosis of ovarian cancer cells through the Hedgehog signaling pathway[J]. Chinese Journal of Family Planning, 2021, 29(12): 2503-2507.
[10] 于凭洋, 苑振楠, 孙冀.lncRNA LINC-PINT 通过miR-425-5p/PTCH1 轴调节喉癌细胞干性[J]. 现代肿瘤医学,2022,30(1):6-10. YU P Y, YUAN Z N, SUN J. Long noncoding RNA LINC-PINT regulates laryngeal carcinoma cell stemness through miR-425-5p/PTCH1 axis [J]. Journal of Modern Oncology, 2022, 30(1): 6-10.
[11] 杨庆军.EGFR 和Cyclin D1 在喉癌组织中的表达及其与预后的相关性[J]. 实用癌症杂志,2022,37(8): 1237-1240. YANG Q J. Correlation analysis of EGFR and cyclin D1 expression in laryngeal carcinoma and prognosis[J]. the Practical Journal of Cancer, 2022, 37(8): 1237-1240.
[12] KHALIFE H, FAYYAD-KAZAN M, FAYYAD-KAZAN H, et al. Lipoic acid alters the microRNA signature in breast cancer cells [J]. Pathology - Research and Practice,2024, 257:155321.
[13] CUI M F, WU Y Y, CHEN M Y, et al. Identification of an miRNA-mRNA regulatory network in colorectal cancer[J]. Combinatorial Chemistry & High Throughput Screening , 2021, 24(10): 1736-1745.
[14] 邓森灵, 兰代群, 曹雅文, 等. 上皮性卵巢癌患者血清miR-362 和miR-485 的表达水平及其与预后的相关性研究[J]. 现代检验医学杂志,2022,37(4):35-37, 42. DENG S L, LAN D Q, CAO Y W, et al. Expression of miR-362 and miR-485 in serum of patients with epithelial ovarian cancer and their correlation with prognosis[J]. Journal of Modern Laboratory Medicine, 2022, 37(4): 35-37, 42.
[15] YAN H L, FAN X H, BAI C M, et al. Sensitive and reliable analysis of endometrial cancer related microRNA using ternary hybridization hairpin probe[J]. Analytical Biochemistry, 2023, 670: 115134.
[16] PANEBIANCO V, PACI P, PECORARO M, et al. A0491-Network analysis integrating microRNA expression profiling with MRI biomarkers and clinical data for prostate cancer early detection: a proof of concept study[J]. European Urology, 2022,81(suppl 1):e744.
[17] YERUKALA SATHIPATI S, AIMALLA N, TSAI M J, et al. Prognostic microRNA signature for estimating survival in patients with hepatocellular carcinoma [J]. Carcinogenesis, 2023, 44(8-9):650-661.
[18] 贺爱军, 任羽, 曹波, 等.miR-425-5p 靶向ZNF423基因调控Notch 信号通路促进胃癌细胞侵袭转移[J].现代消化及介入诊疗,2020,25(6):735-739. HE A J, REN Y, CAO B, et al. MiR-425-5p promotes invasion and metastasis of gastric cancer cells via notch signal pathway by targeting ZNF423[J]. Modern Digestion & Intervention, 2020, 25(6): 735-739.
[19] 姚伟林, 岳红萍.miR-425-5p 在调控宫颈癌HeLa 细胞功能中的作用及其机制[J]. 中国性科学,2020,29 (8):10-14. YAO W L, YUE H P. Role and mechanism of miR-425-Sp in regulating the function of HeLa cells in cervical cancer[J]. Chinese Journal of Human Sexuality, 2020, 29(8): 10-14.
[20] 刘格歌, 陈旺.Hedgehog 信号通路抑制剂在抗肿瘤领域的研究进展[J]. 中国药房,2023,34(8):1014-1019. LIU G G, CHEN W. Research progress of Hedgehog signaling pathway inhibitors in anti-tumor field[J]. China Pharmacy, 2023, 34(8): 1014-1019.
[21] 魏晰麟, 周忠笑, 张健, 等.Hedgehog 信号通路蛋白Ptch1 和Gli1 在胆管癌组织中的表达及意义[J]. 中国普外基础与临床杂志,2016,23(1):70-74. WEI X L, ZHOU Z X, ZHANG J, et al. Expressions and significance of hedgehog ssignaling pathway protein of Ptch1 and Gli1 in cholangiocarcinoma[J]. Chinese Journal of Bases and Clinics in General Surgery, 2016, 23(1): 70-74.
[22] WANG C Y, CHANG Y C, KUO Y L, et al. Mutation of the PTCH1 gene predicts recurrence of breast cancer[J]. Scientific Reports, 2019, 9(1): 16359.
[23] WANG Y N, CHEN H, JIAO X, et al. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients[J]. Cancer Immunology, Immunotherapy, 2022, 71(1): 111-120.
[24] 罗江辉, 毛远舟, 张可贤, 等. 丙泊酚通过miR-802/PTCH1/SHH 通路抑制宫颈癌细胞迁移和侵袭的研究[J]. 中国医院用药评价与分析,2022,22(10):1164-1171. LUO J H, MAO Y Z, ZHANG K X, et al. Inhibition of propofol on migration and invasion of cervical cancer cells through miR-802/PTCH1/SHH pathway [J]. Evaluation and Analysis of Druguse in Hospitals of China, 2022, 22(10): 1164-1171.
[25] 潘岩, 刘鲁明, 花永强. 芹菜素调控PTCH1/GLI1/Bcl-2 轴对胰腺癌细胞增殖、凋亡的影响[J]. 浙江医学,2021,43(16):1734-1738, 后插3. PAN Y, LIU LM, HUA Y Q. Apigenin inhibits proliferation and induces apoptosis of human pancreatic cancer cells through down-regulating PTCH1/GLI1/Bcl-2 axis[J]. Zhejiang Medical Journal, 2021, 43(16): 1734-1738, F0003.
[26] YUAN Z M, XIU C, LIU D M, et al. Long noncoding RNA LINC-PINT regulates laryngeal carcinoma cell stemness and chemoresistance through miR-425-5p/PTCH1/SHH axis [J]. Journal of Cellular Physiology,2019, 234(12):23111-23122.
[27] 于锋, 龚小蓉, 周毅波. 喉癌顺铂耐药细胞株的建立及干性生物学特性分析[J]. 中国耳鼻咽喉颅底外科杂志,2018,24(1):39-44. YU F, GONG X R, ZHOU Y B. Establishment of a cisplatinresistant human laryngeal carcinoma cell line and its stem cell biological characteristics [J]. Chinese Journal of Otorhinolaryngology-Skull Base Surgery, 2018, 24(1): 39-44.
[28] 昝雨欣, 丁妍. 基于加权基因共表达网络探索喉癌干性关键基因[J]. 数理医药学杂志,2024,37(3):171-179. ZAN Y X, DING Y. Identification of stemnessrelated genes in laryngeal cancer by weighted gene co-expression network analysis [J]. Journal of Mathematical Medicine, 2024, 37(3): 171-179.

备注/Memo

备注/Memo:
基金项目：2020 年四川省医学（青年创新）科研课题项目（S20302）。
作者简介：胥然（1985-），男，硕士研究生，主治医师，研究方向：耳鼻喉头颈肿瘤，E-mail：Pb62s9sz5@21cn.com。
通讯作者：蒋振华（1976-），男，硕士研究生，主任医师，研究方向：耳鼻喉头颈肿瘤，E-mail：277284658@qq.com。
更新日期/Last Update: 2025-07-15